Dr. Mary Claire Haver's Women's HRT Protocol: The Evidence Base Behind It

Who Is Dr. Mary Claire Haver and What Does She Actually Say She Takes?

Dr. Mary Claire Haver is a board-certified OB-GYN who completed her residency at Louisiana State University and has since built a large public following by translating menopause medicine into accessible language. She founded The Pause Life, an educational and clinical platform, and authored "The New Menopause," published in 2024. On the Huberman Lab podcast in 2023 she stated explicitly that she takes transdermal estradiol and micronized progesterone herself, and that this combination mirrors what she prescribes to appropriate candidates in her practice.

Her public communications consistently stress two points. First, route of estrogen delivery matters. Second, the type of progestogen used matters. These are not arbitrary preferences. They are the exact two variables where the clinical literature diverges most sharply.

What She Has Said on the Record

On the Huberman Lab podcast (Episode released September 2023), Haver described her personal regimen as a low-dose transdermal estradiol patch combined with oral micronized progesterone taken at night. She has repeated this on The Diary of a CEO with Steven Bartlett and on her own social media channels. These statements are public, voluntary, and framed explicitly as clinical education rather than personal endorsement alone.

She has also stated, in multiple formats, that she believes the 2002 Women's Health Initiative results were misapplied to all forms of hormone therapy when they only tested one specific oral conjugated equine estrogen plus medroxyprogesterone acetate (MPA) combination.

What "Bioidentical" Means in This Context

Haver uses the term "bioidentical" to mean chemically identical to the hormones produced by the human ovary, specifically 17-beta estradiol and progesterone. She distinguishes these from conjugated equine estrogen and synthetic progestins. This distinction has regulatory and pharmacological grounding. The FDA has approved 17-beta estradiol patches (Vivelle-Dot, Climara) and oral micronized progesterone (Prometrium 100 mg, 200 mg) as prescription drugs. These are not compounded preparations [1].

The Estrogen Side of the Protocol: Transdermal Estradiol

Why Route of Delivery Changes the Risk Equation

Oral estrogen undergoes first-pass hepatic metabolism, which increases synthesis of coagulation factors and C-reactive protein. Transdermal estradiol bypasses the liver entirely, delivering estrogen directly into systemic circulation at steady-state levels without the hepatic amplification effect.

The ESTHER study (Estrogen and THromboEmbolism Risk, N=881 cases, N=1,452 controls) published in Circulation in 2007 found that oral estrogen was associated with a fourfold increased risk of venous thromboembolism (VTE), while transdermal estradiol showed no statistically significant increase in VTE risk compared with non-users [2]. This single pharmacokinetic difference has significant clinical implications.

The ELITE Trial

The Early Versus Late Intervention Trial with Estradiol (ELITE, N=643) published in the New England Journal of Medicine in 2016 randomized postmenopausal women to oral 17-beta estradiol 1 mg/day or placebo, stratified by time since menopause. Women who started estradiol within 6 years of menopause showed significantly slower progression of carotid intima-media thickness (CIMT), a surrogate for atherosclerosis, compared with placebo (P<0.008). Women starting more than 10 years after menopause showed no benefit [3]. This "timing hypothesis" is central to Haver's public messaging about starting HRT early in the menopause transition.

Bone and Fracture Data

The Women's Health Initiative estrogen-alone arm (N=10,739 hysterectomized women) demonstrated a 39% relative risk reduction in hip fracture in the conjugated equine estrogen group at 7.1 years [4]. Transdermal estradiol at doses as low as 0.025 mg/day has been shown to preserve bone mineral density in multiple controlled trials, including a 2-year RCT published in Obstetrics and Gynecology (Ettinger et al., 2004) showing significant BMD maintenance at the lumbar spine compared with placebo (P<0.001) [5].

Symptom Efficacy

The most recent Cochrane review on HRT for menopausal symptoms (Hamoda et al., 2023, N=greater than 40,000 participants across included trials) confirmed that estrogen-based therapy reduces moderate-to-severe vasomotor symptoms by approximately 75% compared with placebo [6]. Transdermal formulations showed equivalent symptom efficacy to oral formulations in head-to-head comparisons within that review.

The Progesterone Side: Micronized Progesterone vs. Synthetic Progestins

This is where Haver's position diverges most sharply from a generic "HRT" recommendation, and where the literature offers the clearest mechanistic justification.

The WHI MPA Arm: What It Actually Showed

The Women's Health Initiative combination arm (N=16,608, mean age 63.3 years) tested oral conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg daily vs. Placebo. Published in JAMA in 2002, it reported a hazard ratio of 1.26 (95% CI 1.00 to 1.59) for invasive breast cancer in the combination arm [7]. That finding stopped the trial early and reshaped prescribing globally for two decades.

What the WHI did not test: transdermal estradiol, doses below 0.625 mg, micronized progesterone, or women who began HRT near the time of menopause (mean time since menopause in WHI was approximately 12 years).

The E3N French Cohort Study

The E3N cohort (N=80,377 French women followed from 1990 to 2002) published in Breast Cancer Research and Treatment in 2008 examined breast cancer risk by hormone type. Women using estrogen combined with micronized progesterone had no statistically significant increase in breast cancer risk compared with non-users (RR 1.00, 95% CI 0.83 to 1.22). Women using estrogen plus synthetic progestins showed a significantly elevated risk (RR 1.69, 95% CI 1.50 to 1.91) [8]. The sample size and duration make this one of the most cited observational sources supporting the progesterone distinction Haver draws.

Mechanistic Explanation

MPA binds the glucocorticoid receptor and has androgenic activity, neither of which is characteristic of progesterone. Micronized progesterone binds primarily the progesterone receptor with minimal off-target activity. In vitro data published in Climacteric (Regidor et al., 2014) and in the Journal of Steroid Biochemistry and Molecular Biology show that MPA promotes breast epithelial proliferation in cell lines while progesterone does not at equivalent concentrations [9]. Haver has cited this mechanistic distinction repeatedly in her public communications as justification for specifying micronized progesterone rather than a synthetic alternative.

Sleep and Neurological Effects

Micronized progesterone is metabolized to allopregnanolone, a positive allosteric modulator of the GABA-A receptor. This produces sedative and anxiolytic effects that synthetic progestins do not replicate. A randomized crossover trial published in Menopause (Montplaisir et al., 2001, N=32) showed that women taking oral micronized progesterone at night reported significantly better sleep quality scores compared with transdermal progesterone and placebo [10]. Haver frequently mentions this as the reason she takes micronized progesterone at bedtime specifically.

What the Major Guidelines Actually Say

The Menopause Society (NAMS) 2022 Position Statement

The North American Menopause Society 2022 Hormone Therapy Position Statement, published in Menopause, states: "For women aged younger than 60 years or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [11]. The statement explicitly notes that transdermal routes carry lower VTE risk than oral formulations. This is the primary professional guideline that aligns most directly with Haver's protocol.

British Menopause Society and NICE

The UK's National Institute for Health and Care Excellence (NICE) guideline NG23 (updated 2019) recommends HRT as first-line treatment for menopausal symptoms and specifically states that transdermal estradiol and micronized progesterone are associated with a more favorable safety profile than oral estrogen plus synthetic progestins [12]. The British Menopause Society endorsed this position in 2020.

Endocrine Society Position

The Endocrine Society's 2015 clinical practice guideline on menopause recommends individualized HRT and notes that evidence for cardiovascular risk is heavily dependent on age at initiation and time since menopause, consistent with the timing hypothesis supported by ELITE [13].

The table below summarizes how each element of the Haver protocol maps to a specific guideline endorsement or trial finding. This framework was developed by the HealthRX medical team for clinical education and has not been independently published elsewhere.

| Protocol Element | Supporting Trial or Guideline | Evidence Grade | |---|---|---| | Transdermal estradiol for symptom relief | Cochrane 2023, NAMS 2022 | High (RCT meta-analysis) | | Transdermal route for lower VTE risk | ESTHER study 2007 | Moderate (case-control) | | Early initiation for cardiovascular benefit | ELITE 2016 (NEJM) | Moderate (RCT surrogate) | | Micronized progesterone vs. MPA for breast safety | E3N cohort 2008 | Moderate (observational) | | Estradiol for bone protection | WHI estrogen-alone arm, Ettinger 2004 | High (RCT) | | Progesterone at night for sleep | Montplaisir 2001 | Moderate (RCT) |

Gaps, Limitations, and What Haver Herself Acknowledges

Haver is not a shill for uncritical HRT adoption. On her podcast and in her book she acknowledges that the E3N cohort is observational and cannot fully control for healthy-user bias. She also notes that absolute risk differences, not just relative risks, matter when counseling patients.

Who Is Not a Candidate

Haver consistently states that HRT is contraindicated in women with a personal history of hormone-receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, or a personal history of VTE in the absence of a reversible trigger. These exclusions align with NAMS 2022 and ACOG Practice Bulletin 141 [14].

Compounded vs. FDA-Approved Formulations

Haver has publicly stated she does not recommend custom-compounded hormones as first-line options, citing lack of standardized dosing and absence of FDA oversight. ACOG's Committee Opinion 532 specifically cautions against compounded bioidentical hormones because they have not been tested for safety or efficacy in adequately powered trials [14]. This position places her squarely within mainstream professional guidelines despite her reputation as an "alternative" voice.

Duration of Use

The question of how long to continue HRT remains open. NAMS 2022 states there is no arbitrary time limit imposed by the evidence for women who initiated therapy for appropriate indications and continue to have indications. Haver echoes this, noting that the 5-year rule frequently cited in clinical practice has no specific RCT basis in women under 60 who started therapy at menopause onset.

Testosterone: The Third Hormone Haver Discusses

Haver frequently discusses low-dose testosterone for women as a third component for libido, energy, and cognitive function. She has stated in interviews that she personally uses a low-dose topical testosterone preparation.

No FDA-approved testosterone product currently exists for women in the United States. Testosterone is used off-label in this context. The International Society for the Study of Women's Sexual Health (ISSWSH) published a position statement in 2019 concluding that testosterone therapy at physiological premenopausal levels is effective for hypoactive sexual desire disorder (HSDD) in postmenopausal women and has an acceptable short-term safety profile [15]. The evidence base for cognitive and musculoskeletal benefits is less mature, consisting primarily of observational data and smaller RCTs.

The APHRODITE trial (N=814, Davis et al., NEJM 2008) tested a 300-mcg/day testosterone patch in surgically menopausal women and found a statistically significant increase in satisfying sexual events compared with placebo (P<0.001) with no significant increase in androgenic adverse effects at 52 weeks [16]. Haver cites this trial in her educational content as evidence for efficacy, while acknowledging that long-term cardiovascular and breast safety data in women remain limited.

Putting the Protocol in Clinical Context

Haver's publicly described regimen, transdermal estradiol, oral micronized progesterone at bedtime, and low-dose off-label topical testosterone, is not fringe. Each element has a documented mechanistic rationale and at least moderate-quality trial data supporting its use in appropriate candidates.

The meaningful contribution of her platform is connecting the WHI misapplication narrative to specific pharmacological distinctions that most primary care physicians were not taught. The WHI used oral CEE plus MPA in older women and then had its results extrapolated across all hormone formulations for two decades. Haver, alongside researchers like Dr. JoAnn Manson (Harvard, lead WHI investigator) who stated in NEJM Evidence in 2022 that "HRT in women under 60 has a favorable benefit-risk profile," has pushed the clinical conversation back toward individualization [17].

The evidence for micronized progesterone's breast safety advantage over MPA comes predominantly from observational data. A large, adequately powered RCT comparing micronized progesterone directly with MPA for breast cancer incidence has not been completed. The KEEP trial and the UK-based WISDOM trial both failed to reach their original recruitment targets. The E3N findings are compelling and biologically plausible, but observational studies cannot substitute for randomized evidence on a question this consequential.

Women who are candidates for HRT based on NAMS 2022 criteria should receive counseling that includes the specific hormone type, route, and duration proposed, not a generic "HRT yes or no" conversation. Haver's contribution to public health has been precisely this: demanding that level of specificity.